Onconetix financials
$0.8200−26.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $815.4K | $2.5M | $58.5K |
| Gross profit | $632.9K | $1.1M | -$1.1M |
| Gross margin | 77.6% | 41.8% | −1927.9% |
| Operating income | -$17.9M | -$56.5M | -$36.0M |
| Net income | -$15.5M | -$58.9M | -$37.4M |
| Net margin | −1904.8% | −2333.4% | −63986.5% |
| Diluted EPS | $-828.00 | $-91169.50 | $-371662.50 |
| EBITDA | -$6.3M | -$9.6M | -$17.8M |
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M |
| Free cash flow | -$9.7M | -$10.5M | -$13.6M |
| Diluted shares | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $5.2M | $646.5K | $4.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $9.3M | $118.9K |
| Total assets | $24.9M | $28.2M | $87.5M |
| Total liabilities | $9.2M | $18.6M | $21.9M |
| Shareholders' equity | $15.8M | $8.5M | $1.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology